Texas Biomed Staff

Marie-Claire Gauduin

Associate Scientist | Virology and Immunology and SNPRC
Phone: 210-258-9844
Send E-mail


Summary

Gauduin’s laboratory is investigating the early events of SIV transmission in macaque using a recombinant SIV tagged with a “green fluorescent protein” as a sensitive tool to monitor infected cells in vivo. This construct allows the team to identify: 1) the initial infected cells, their phenotype and function; 2) the mechanisms involved, time course and routes of viral spread from the site of initial infection to lymphoid organs and blood; and 3) the generation of early SIV-specific immune response from the mucosal site of infection. This is critical for the development of effective vaccines.

Maternal transmission of HIV-1 accounts for most cases of pediatric HIV-1 infection. Gauduin’s group is investigating the early virus-specific T cell responses in neonates orally infected with a pathogenic or non-pathogenic strain of simian immunodeficiency virus (SIV), an HIV laboratory surrogate. She has shown that newborn monkeys infected with a less pathogenic SIV can control infection even in the absence of antiviral treatment, which suggests that treatment may be quite successful in "rescuing" or preserving the infant’s immune response. The laboratory is now focusing on defining the mechanisms involved in oral SIV transmission to develop effective strategies to successfully block SIV transmission.

One key obstacle to an effective AIDS vaccine has been the inability to deliver antigen for a sufficient period of time leading to weak and transient protection. Because HIV transmission occurs predominantly across mucosal surfaces, the ideal vaccine strategy would be to target HIV at mucosal entry sites of transmission to prevent infection. Gauduin proposes to develop a novel genetic vaccine strategy that delivers viral proteins. A promoter will drive antigen expression and stem cells will continuously yield new (daughter) antigenproducing cells without being eliminated by the immune response.

TB is the leading cause of death among people with HIV, and pregnant women living with active TB and HIV are at far greater risk of maternal mortality than those without HIV infection Gauduin has established an experimental acute M. tuberculosis infection in the newborn primate model to produce progressive and/ or active but asymptomatic infections that mimic the clinical and pathologic effects of pediatric tuberculosis. The ultimate goal is to optimize neonatal primate model for TB/HIV co-infection to study immunopathogenesis of TB/SIV interactions, the impact of treatment and treatment interruption on the evolution of tuberculosis.

Gauduin’s Team

  • Gregory Bonello, Ph.D        Staff Scientist
  • Mary Salas, M.S.               Senior Research Associate
  • Robert White, M.S.            Senior Research Associate
  • Magdalena Cepeda, B.S.    Research Assistant 
  • Jessica Folwarczny, B.S.     Graduate Student
  • Peter Lentz, B.S.               Graduate Student
  • Philippe Blancou, Ph.D.      Visiting Scientist (France)

 

Education

Doctoral Degree: Ph.D. Microbiology (1996)

New York University School of Medicine New York, NY
Dissertation:

Gauduin M-C.  Role of neutralizing antibodies to the envelope glycoprotein of human immunodeficiency virus in protective immunity (Animal model: Hu-PBL-SCID mouse) [Dissertation].  New York University - School of Medicine and the Aaron Diamond AIDS Research Center, New York, NY  1996; 215 pp. Supervisor:  Dr. Richard A. Koup.


Master's Degree:

1993, M.S. Basic Medical Sciences, New York University School of Medicine New York, NY; 1989, M.S. summa cum laude, Immunology, University of Paris VII - La Sorbonne
Thesis:

Gauduin M-C.  Suppression of in vitro lymphocyte function by a synthetic peptide, CKS-17: Modulation of suppression by muramyl dipeptide. [Dissertation]  University of Paris VII - La Sorbonne, Ecole Pratique des Hautes Etudes, Paris, France; and the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 1989; 99 pp. Supervisors: Drs. L. Chedid and F. Aubibert.


Postdoctoral Work

1996-1999: Research Fellow in Medicine, Harvard Medical School and the New England Regional Primate Research Center, Department of Immunology, Southborough, MA

1999-2006: Instructor in Medicine, Harvard Medical School, New England Primate Research Center, and Massachusetts General Hospital (MGH)- Infectious Disease Unit, Boston, MA

Research Focus

1. Nonhuman Primate Models for the Study of Infectious Diseases
2. Mechanisms of HIV Transmission and Immunopathogenesis
3. Mucosal Immunity and AIDS Vaccine Development
4. Pediatric AIDS: Innate and Adaptive Immunity
5. Mechanisms of HIV/TB co-infection in Pediatric AIDS

Awards and Honors

1989 M.S., summa cum laude, University of Paris VII - La Sorbonne 

1992-1995   Pediatric AIDS Foundation, Student Intern Awards-4 years 

1998-2000    Pediatric AIDS Foundation Scholar Award 1998

2000-2003    Pediatric AIDS Foundation, Basic Grant Award 2000

2006         Founder’s Council Equipment Award, San Antonio TX

2007         Foundation Forum Research Award, San Antonio TX

2008         Founder’s Council Equipment Award, San Antonio TX

2008         Martin Goland Research Award, SIGMA XI, San Antonio TX

2009         The Steves Award - Foundation Forum, San Antonio TX

 

Publications

High cell-free virus load and robust autologous adaptive immune responses in breast milk of SIV-infected African green monkeys

Wilks AB, Perry JR, Ehlinger EP, Zahn RC, White B, Gauduin MC, Carville A, Seaman MS, Schmitz JE, Permar AR
J Virol 85: 9517-26, 2011
PubMed ID: 21734053

Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery.

Mansfield K, Lang SM, Gauduin M-C, Sanford HB, Lifson JD, Johnson RP, Desrosiers RC.
J Virol 82 (8): 4135-4148, 2008
PubMed ID: 18272584

Grants

Dr. Gauduin’ s research is currently supported by the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and the National Center for Research Resources (NCRR)